← Signals · Healthcare · TSX
$GUD
Knight Therapeutics Inc.
Signal as of N/A  ·  90-day rolling window  ·  Pharmaceuticals
Confluence Score
out of 100  ·  Full breakdown →
Score delayed 7 days on Free  ·  See today's score — Analyst →
Signals scoring 20–39 have historically hit 47% of the time (avg +6.8% over 90 days, 105 backtested signals). Methodology →
🔒 Risk monitoring — insider-selling & reversal warnings (Analyst)
📅 Buying into earnings — Aug 06 (28d)
Confluence Score
Insider Activity (90d)
5
1 buyer  ·  $413K  ·  open-market only
Current Price
$9.98
CAD  ·  5-min cache
Market Cap
$980M
CAD  ·  TMX
Lobbying & Contracts
None
0 regs  ·  0 contracts
Healthcare on Form55: 43% hit rate · -5.4% alpha vs XIU.TO · 21 closed signals Track Record →
Signal Analyst
The Confluence Score and insider trade feed above are free. Signal Analyst adds the full component breakdown, lobbying registrations, and contract wins — plus alerts when this company's signal moves, so you don't have to keep checking back.
Monitor — CAD $29/mo
Price Chart
12 months daily  ·  TSX:GUD
Insider Transactions
90-day window  ·  29 filings
Date Insider Role Nature Dir. Shares Buy Price Return Value
Jun 15, 2026 Khouri, Amal Plan / DRIP Buy 774 $9.36 +6.6%  · 24d $7K
Jun 15, 2026 Khouri, Amal Plan / DRIP Buy 593 $5.22 +91.2%  · 24d $3K
Jun 15, 2026 Utchanah, Arvind Plan / DRIP Buy 695 $9.36 +6.6%  · 24d $7K
Jun 15, 2026 Utchanah, Arvind Plan / DRIP Buy 296 $5.22 +91.2%  · 24d $2K
Jun 15, 2026 Goodman, Jonathan Ross Plan / DRIP Buy 718 $9.36 +6.6%  · 24d $7K
Jun 15, 2026 Goodman, Jonathan Ross Plan / DRIP Buy 267 $5.22 +91.2%  · 24d $1K
Jun 15, 2026 Emblem, Susan Caroline Plan / DRIP Buy 876 $9.36 +6.6%  · 24d $8K
Jun 15, 2026 Emblem, Susan Caroline Plan / DRIP Buy 361 $5.22 +91.2%  · 24d $2K
Jun 15, 2026 Sakhia, Samira Plan / DRIP Buy 1,934 $9.36 +6.6%  · 24d $18K
Jun 15, 2026 Sakhia, Samira Plan / DRIP Buy 720 $5.22 +91.2%  · 24d $4K
Jun 15, 2026 Dos Santos Dias, Henrique José Plan / DRIP Buy 140 $5.22 +91.2%  · 24d $731
Jun 15, 2026 Lopez, German Plan / DRIP Buy 794 $9.36 +6.6%  · 24d $7K
Jun 15, 2026 Lopez, German Plan / DRIP Buy 200 $5.22 +91.2%  · 24d $1K
Jun 10, 2026 Groleau, Melanie Exercise Sell 4,390 $6.21 $27K
Jun 10, 2026 Groleau, Melanie Exercise Buy 4,390 $6.21 +60.7%  · 29d $27K
Jun 10, 2026 Groleau, Melanie Open Market Buy 4,390 $9.25 +7.9%  · 29d $41K
Jun 10, 2026 Groleau, Melanie Exercise Sell 4,039 $5.72 $23K
Jun 10, 2026 Groleau, Melanie Exercise Buy 4,039 $5.72 +74.5%  · 29d $23K
Jun 10, 2026 Groleau, Melanie Open Market Buy 4,039 $9.25 +7.9%  · 29d $37K
Jun 10, 2026 Groleau, Melanie Exercise Sell 4,039 $5.72 $23K
Jun 10, 2026 Groleau, Melanie Exercise Sell 1,709 $7.02 $12K
Jun 10, 2026 Groleau, Melanie Exercise Buy 1,709 $7.02 +42.2%  · 29d $12K
Jun 10, 2026 Groleau, Melanie Open Market Buy 1,709 $9.25 +7.9%  · 29d $16K
Jun 10, 2026 Groleau, Melanie Exercise Sell 5,129 $7.02 $36K
Jun 10, 2026 Groleau, Melanie Exercise Buy 5,129 $7.02 +42.2%  · 29d $36K
Jun 10, 2026 Groleau, Melanie Open Market Buy 5,129 $9.25 +7.9%  · 29d $47K
Jun 10, 2026 Groleau, Melanie Exercise Sell 29,403 $7.73 $227K
Jun 10, 2026 Groleau, Melanie Exercise Buy 29,403 $7.73 +29.1%  · 29d $227K
Jun 10, 2026 Groleau, Melanie Open Market Buy 29,403 $9.25 +7.9%  · 29d $272K
Score uses open-market buys only  ·  5 open-market  ·  18 plan / compensation shown but not scored  ·  Return is unrealized, to today's price; a “· Nd” mark means the 90-day window is still open (N of 90 days) — too early to judge.
Score Breakdown
Signal Analyst  ·  $29/mo
Component Points Max Detail Weight
Conviction (unique buyers)  ✓ FREE PREVIEW 30 30 1 unique buyer (maximum conviction)
Buy/sell ratio 20 45% buys (5B / 6S)
Dollar value 25 $413K
Lobbying activity 15 None
Contract wins 10 None
Insider track record 10 No track record data
Private placements 8 None
Confluence bonus 10 None
Cluster timing (velocity) 10 No coordinated buying cluster detected
Buy/sell reversal pattern 8 No buy/sell reversal pattern
Total 0 100
Unlock Component Detail — CAD $29/mo
Buying Insiders
Open-market · 90 days · 1 unique buyer
Insider Credibility Hit Rate Avg 90d Return Trades (eval'd) Buy Value (90d) Last Buy
Groleau, Melanie $413K Jun 10, 2026
Credibility score: historical hit rate × avg 90d return × sample size. View full insider leaderboard →
Lobbying Registrations
OCL active  ·  none found
No active OCL lobbying registrations in the last 90 days. Analyst plan →
Government Contract Wins
90-day window  ·  none found
No government contract wins in the last 90 days. Analyst plan →
Private Placements
12 months  ·  Signal Analyst  ·  $29/mo
Private placement history, deal size, and lock-up expiry tracking. Analyst plan →
Indigenous Consultation
no records on file

No Indigenous consultation records on file for GUD.

SEDAR+ Filings
official filing registry
Form55 monitors SEDAR+ filing alerts and newswire announcements for Technical Reports and material changes. Search SEDAR+ →
Short Interest
CIRO  ·  Jun 30, 2026
Shares short
1,415,789
Net change
-204,098 (-12.6%)
History
Jun 30: 1,415,789
Jun 15: 1,619,887
May 31: 1,729,108
May 15: 1,801,807
Apr 30: 1,861,011
Apr 15: 1,912,154
Aggregate short position from CIRO's Consolidated Short Position Report (published twice monthly).
Wikipedia Attention
Pageviews  ·  30 days
Views (30d)
653
Daily English-Wikipedia pageviews (Wikimedia). Traffic spikes often coincide with news — a public-attention indicator, not investment advice.
Clinical Trials
ClinicalTrials.gov  ·  6 trials
Phase Status Trial Updated
P2 Completed Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy I Jul 2021
P2 Completed Miltefosine to Treat Mucocutaneous Leishmaniasis Sep 2020
Completed Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) Sep 2020
Completed Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefos Mar 2019
Withdrawn Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Reg Apr 2025
Withdrawn Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Aug 2020
Trials where this company is the lead sponsor (ClinicalTrials.gov). Phase advances, completions and terminations are material catalysts for clinical-stage companies — not investment advice.
Form55 provides data and analysis for informational purposes only. Nothing on this site constitutes investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.